| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 06/05/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/26/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 05/12/2023 | 203.03% | SVB Leerink | → $4 | Upgrades | Market Perform → Outperform |
| 05/12/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 03/30/2023 | 506.06% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 01/24/2023 | 127.27% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 10/04/2022 | 506.06% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
| 08/11/2022 | 203.03% | SVB Leerink | $8 → $4 | Downgrades | Outperform → Market Perform |
| 05/17/2022 | 278.79% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/06/2022 | 733.33% | Morgan Stanley | $45 → $11 | Downgrades | Overweight → Equal-Weight |
| 11/10/2021 | 2400% | SVB Leerink | $35 → $33 | Maintains | Outperform |
| 08/16/2021 | 2551.52% | SVB Leerink | $34 → $35 | Maintains | Outperform |
| 05/17/2021 | 2400% | SVB Leerink | $37 → $33 | Maintains | Outperform |
| 04/06/2021 | 2703.03% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 03/02/2021 | 2930.3% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 03/02/2021 | 3081.82% | Guggenheim | → $42 | Initiates Coverage On | → Buy |
| 03/02/2021 | 3309.09% | Morgan Stanley | → $45 | Initiates Coverage On | → Overweight |
| 03/02/2021 | 2627.27% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
What is the target price for Bolt Biotherapeutics (BOLT)?
The latest price target for Bolt Biotherapeutics (NASDAQ: BOLT) was reported by HC Wainwright & Co. on August 3, 2023. The analyst firm set a price target for $8.00 expecting BOLT to rise to within 12 months (a possible 506.06% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bolt Biotherapeutics (BOLT)?
The latest analyst rating for Bolt Biotherapeutics (NASDAQ: BOLT) was provided by HC Wainwright & Co., and Bolt Biotherapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Bolt Biotherapeutics (BOLT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bolt Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bolt Biotherapeutics was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
Is the Analyst Rating Bolt Biotherapeutics (BOLT) correct?
While ratings are subjective and will change, the latest Bolt Biotherapeutics (BOLT) rating was a reiterated with a price target of $0.00 to $8.00. The current price Bolt Biotherapeutics (BOLT) is trading at is $1.32, which is within the analyst's predicted range.
